

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

RECEIVED

FEB 04 2002

TECH CENTER 1600/2900

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216


For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-308-6900

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE



TELEPHONE: 512/474-5201
FACSIMILE: 512/536-4598

WRITER'S INTERNET ADDRESS:
GSHISHIMA@FULBRIGHT.COM

WRITER'S DIRECT DIAL NUMBER:
512/536-3081

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

1647
Box 1500

November 30, 2001

FILE: UTSD:578USC2
10020402

RECEIVED

FEB 04 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

November 30, 2001
Date

Steven L. Highlander

Commissioner for Patents
Washington, DC 20231

RE: *U.S. Patent Application No. 09/603,131 Entitled: METHOD AND SCREENING FOR AGONISTS OF LXR TRANSCRIPTION - by David J. Mangelsdorf and Bethany A. Janowski (Client Reference No. UTSMD/DAL:578)*

Commissioner:

Enclosed for filing in the above-referenced patent application is:

- (1) Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
- (2) Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Dated October 2, 2001;
- (3) Statement as Required Under 37 C.F.R. § 1.821(f); Paper Copy of Sequence Listing; Computer Readable Form (CRF); and
- (4) Response To Restriction Requirement Dated October 2, 2001;
- (5) Request For Extension of Time to Respond to Office Communication Dated October 2, 2001

~~01/29/2002 SDENB001 00000035 09603131~~

01 FC:215


55.00 OP

Commissioner for Patents
November 30, 2001
Page 2

- (7) A check for \$55.00 as the fee for the extension of time; and
- (6) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

If the check is inadvertently omitted, or the amount is insufficient, or should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, or should an overpayment be included herein, the Commissioner is authorized to deduct or credit said fees from or to Fulbright & Jaworski L.L.P. Account No.: 50-1212/10020402/SLH.

Respectfully submitted,




Steven L. Highlander
Reg. No. 37,642

SLH/cpj
Encl.: As stated

RECEIVED
FEB 04 2002
TECH CENTER 1600/2900



CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below.	
November 30, 2001 Date	 Steven L. Highlander

RECEIVED
FEB 04 2002
TECH CENTER 1600/2900

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

David J. Mangelsdorf and
Bethany A. Janowski

Group Art Unit: 1646

Examiner: Pak, M.

Serial No.: 09/603,131

Atty. Dkt. No.: UTSD:578USC2/SLH

Filed: June 23, 2001

For: METHOD AND SCREENING FOR
AGONISTS OF LXRA TRANSCRIPTION

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES DATED OCTOBER 2, 2001**

Commissioner for Patents
Washington, D.C. 20231

Commissioner:


This is in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated October 2, 2001, the deadline for response having been extended to December 2, 2001, by virtue of the attached Petition for Extension of Time, and payment of fees. Should applicants' check be missing, or should any other fees be due, applicants authorize the Commissioner to debit Fulbright & Jaworski Deposit Account No. 55-1212/10020402/SLH.

RESPONSE TO NOTICE

Submitted herewith is a Statement As Required Under 37 C.F.R. § 1.821(f); paper copy of sequence listing and computer readable form (CRF) which comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures.

Applicants believe that the attached documents fully respond to the Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures for this application.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201
(512) 536-4598 (facsimile)

Date: November 30, 2001